Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Dec;103(6):531-541.
doi: 10.1111/ejh.13319. Epub 2019 Sep 18.

Autoimmune thrombocytopenia: Current treatment options in adults with a focus on novel drugs

Michał Witkowski  1 , Magdalena Witkowska  1   2 , Tadeusz Robak  1   3
Affiliations
Review

Autoimmune thrombocytopenia: Current treatment options in adults with a focus on novel drugs

Michał Witkowski et al. Eur J Haematol. 2019 Dec.

Abstract

Immune thrombocytopenia (ITP) is an autoimmune disease characterized by platelet destruction and reduced platelet production resulting in decreased platelet level and an increased risk of bleeding. Based on the immunologic mechanism of ITP, front-line standard therapy consists of corticosteroids and intravenous immunoglobulins (IVIG). If patients do not respond to the first-line treatment, or if continuous therapy is required, the disorder is called refractory ITP, and second-line therapy is indicated. This treatment may consist of rituximab, thrombopoietin receptor agonists, splenectomy, or cytotoxic drugs. Despite significant advances, many patients do not respond to any the treatments listed below, and new treatment options need to be developed for this relapsed and refractory group. Recent clinical studies have indicated promising outcomes for novel drugs, either as single agents or in combination with traditional drugs. This review discusses the latest and the most promising novel drugs for ITP in adults.

Keywords: avatrombopag; eltrombopag; immune thrombocytopenia; indirubin; receptor antagonist; rituximab; romiplostim; rozanolixizumab; rozrolimupab; thrombopoietin.

PubMed Disclaimer

References

REFERENCES

    1. Onisâi M, Vlădăreanu AM, Spînu A, Găman M, Bumbea H. Idiopathic thrombocytopenic purpura (ITP) - new era for an old disease. Rom J Intern Med. 2019. [Epub ahead of print]
    1. Kapur R, Zufferey A, Boilard E, Semple JW. Nouvelle cuisine: platelets served with inflammation. J Immunol. 2015;194:5579-5587.
    1. Iraqi M, Perdomo J, Yan F, Choi PH, Chonget BH. Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro. Haematologica. 2015;100:623-632.
    1. Zufferey A, Kapur R, Semple JW. Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP). J. Clin. Med. 2017;6:16.
    1. Nampoothiri RV, Singh C, Lad D, et al. Immune thrombocytopenia is still the commonest diagnosis on consultative hematology. Indian J Hematol Blood Transfus. 2019;35:352-356.

MeSH terms

LinkOut - more resources